171 related articles for article (PubMed ID: 21969130)
21. Elevated Expression of EPHA2 Is Associated With Poor Prognosis After Radical Prostatectomy in Prostate Cancer.
Kurose H; Ueda K; Kondo R; Ogasawara S; Kusano H; Sanada S; Naito Y; Nakiri M; Nishihara K; Kakuma T; Akiba J; Igawa T; Yano H
Anticancer Res; 2019 Nov; 39(11):6249-6257. PubMed ID: 31704854
[TBL] [Abstract][Full Text] [Related]
22. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
23. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
24. Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea.
Kim JK; Cho SY; Jeong CW; Lee SB; Ku JH; Hong SK; Byun SS; Kwak C; Him HH; Lee SE; Jeong H
BJU Int; 2012 Aug; 110(4):505-9. PubMed ID: 22314007
[TBL] [Abstract][Full Text] [Related]
25. The significance of micro-lymphatic invasion and pathological Gleason score in prostate cancer patients with pathologically organ-confined disease and negative surgical margins after robot-assisted radical prostatectomy.
Hashimoto T; Nakashima J; Inoue R; Komori O; Yamaguchi Y; Kashima T; Satake N; Nakagami Y; Namiki K; Nagao T; Ohno Y
Int J Clin Oncol; 2020 Feb; 25(2):377-383. PubMed ID: 31673831
[TBL] [Abstract][Full Text] [Related]
26. The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence.
Cao D; Kibel AS; Gao F; Tao Y; Humphrey PA
Am J Surg Pathol; 2010 Jul; 34(7):994-1001. PubMed ID: 20505501
[TBL] [Abstract][Full Text] [Related]
27. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
[TBL] [Abstract][Full Text] [Related]
28. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
29. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
[TBL] [Abstract][Full Text] [Related]
30. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
31. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
32. Controversial predictors of biochemical recurrence after radical prostatectomy: a study from a Latin American (Brazilian) institution.
Noronha MR; Quintal MM; Magna LA; Reis LO; Billis A; Meirelles LR
Int Braz J Urol; 2013; 39(6):779-92. PubMed ID: 24456770
[TBL] [Abstract][Full Text] [Related]
33. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic performance of
Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
[TBL] [Abstract][Full Text] [Related]
35. The usefulness of touch preparation cytological evaluation and prostatic capsule involvement in prediction of prostate cancer recurrence.
Brannigan RE; Shin E; Rademaker A; Oyasu R; Huang CF; Pearle MS; McVary KT
J Urol; 1998 Nov; 160(5):1741-7. PubMed ID: 9783944
[TBL] [Abstract][Full Text] [Related]
36. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
Bauman TM; Ewald JA; Huang W; Ricke WA
BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
[TBL] [Abstract][Full Text] [Related]
37. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
38. A close surgical margin after radical prostatectomy is an independent predictor of recurrence.
Lu J; Wirth GJ; Wu S; Chen J; Dahl DM; Olumi AF; Young RH; McDougal WS; Wu CL
J Urol; 2012 Jul; 188(1):91-7. PubMed ID: 22578729
[TBL] [Abstract][Full Text] [Related]
39. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.
Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME
BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.
Leisser A; Pruscha K; Ubl P; Wadsak W; Mayerhöfer M; Mitterhauser M; Hacker M; Kramer G; Shariat S; Karanikas G; Hartenbach M; Haug AR
Prostate; 2015 Nov; 75(15):1760-7. PubMed ID: 26282590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
